There are 2789 resources available
618P - Apalutamide (APA) for advanced prostate cancer in older patients (pts): Combined analysis of TITAN & SPARTAN
Presenter: John Shen
Session: ePoster Display
672P - Real-world study of cabozantinib in patients with advanced renal cell carcinoma (aRCC) after VEGF-targeted therapy (CASSIOPE): Interim data for patients who had received prior nivolumab
Presenter: Giuseppe Procopio
Session: ePoster Display
674P - WITNESS: Real-world outcomes of patients (pts) with advanced renal cell carcinoma (aRCC) treated with nivolumab in France and subgroup analysis of patients receiving concomitant medications at baseline
Presenter: Antoine Thiery-Vuillemin
Session: ePoster Display
621P - Efficacy and safety of relugolix vs leuprolide (LEU) in men with advanced prostate cancer (APC): Clinical subgroup analysis from the phase III HERO study
Presenter: Bertrand Tombal
Session: ePoster Display
622P - Geographical assessment of efficacy and safety of relugolix: A subgroup analysis from the randomized, phase III HERO study vs leuprolide (LEU) in men with advanced prostate cancer (APC)
Presenter: Bertrand Tombal
Session: ePoster Display
678P - Cytoreductive nephrectomy (CN) for patients with metastatic sarcomatoid and/or rhabdoid (S/R) renal cell carcinoma (RCC) treated with immune checkpoint inhibitors (ICI)
Presenter: Andrew Hahn
Session: ePoster Display
624P - Prevalence and clinical impact of PTEN status in patients (pts) with de novo metastatic hormone sensitive prostate cancer (mHSPC)
Presenter: Jonathan Thouvenin
Session: ePoster Display
625P - TMPRSS2-ERG expression and clinical evolution of metastatic hormone sensitive prostate cancer
Presenter: Caterina Aversa
Session: ePoster Display
681P - Real-world (RW) clinical outcomes for metastatic renal cell carcinoma (mRCC)
Presenter: Saby George
Session: ePoster Display